NGM Biopharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David J. Woodhouse
- Full Time Employees
- 138
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 333 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Apr 4, 2019
- CIK
- 0001426332
- Website
- ngmbio.com
- Similar Companies
- Business
- NGM Biopharmaceuticals, Inc. (NGM Bio) is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics targeting key biological pathways for cardio-metabolic, liver, oncologic, retinal, and ophthalmic diseases; its pipeline includes NGM120, a GDF15/GFRAL antagonist antibody in Phase 2 trials for hyperemesis gravidarum and cancer cachexia, aldafermin, an engineered FGF19 analog with orphan drug designation pursuing a registrational trial in primary sclerosing cholangitis, NGM707, an ILT2/ILT4 dual antagonist monoclonal antibody in Phase 1/2 trials for advanced solid tumors often in combination with pembrolizumab, NGM831 and NGM438, ILT3 and LAIR1 antagonist antibodies respectively in early clinical stages for oncology, and earlier assets such as NGM621 for geographic atrophy and NGM936, an ILT3 x CD3 bispecific antibody for hematologic malignancies. Founded in 2007 and headquartered in South San Francisco, California, the company maintains ongoing research collaborations and license agreements with Merck & Dohme Corp. focused on ophthalmology, cardiovascular, metabolic diseases including heart failure, and oncology targets. In April 2024, NGM Bio transitioned to a private entity through a $135 million acquisition by affiliates of The Column Group, its largest shareholder, enabling greater operational flexibility following prior clinical setbacks and workforce reductions; subsequently in July 2024, it secured $122 million in Series A funding led by The Column Group to advance Phase 2 trials of NGM120 in hyperemesis gravidarum and a registrational study of aldafermin in primary sclerosing cholangitis, with both initiating in Q4 2024, while continuing to prioritize NGM707 development based on encouraging early data.
Quaise Energy and Nevada Gold Mines Partner on Deep Geothermal Pilot Plant to Decarbonize Mining
NGM Bio Announces Closing of Tender Offer
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference